Your browser doesn't support javascript.
loading
An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes.
Bertaina, Alice; Abraham, Allistair; Bonfim, Carmem; Cohen, Sandra; Purtill, Duncan; Ruggeri, Annalisa; Weiss, Daniel; Wynn, Robert; Boelens, Jaap Jan; Prockop, Susan.
Affiliation
  • Bertaina A; Center for Cancer and Immunology Research, CETI, Children's National Hospital, Washington, District of Columbia, USA.
  • Abraham A; Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California, USA.
  • Bonfim C; Pediatric Bone Marrow Transplantation Division, Hospital Pequeno Principe, Curitiba, Brazil.
  • Cohen S; Université de Montréal and Maisonneuve Rosemont Hospital, Montréal, Québec, Canada.
  • Purtill D; Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
  • Ruggeri A; IRCCS Ospedale San Raffaele, Segrate, Milan, Italy.
  • Weiss D; University of Vermont, Burlington, Vermont.
  • Wynn R; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
  • Boelens JJ; Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, and Department of Pediatrics, Weill Cornell Medical College of Cornell University, New York, New York, USA.
  • Prockop S; Stem Cell Transplant Program, Division of Hematology/Oncology Boston Children's Hospital and Department of Pediatric Oncology, Dana Farber Cancer Institute. Electronic address: susan.prockop@childrens.harvard.edu.
Cytotherapy ; 24(4): 385-392, 2022 04.
Article in En | MEDLINE | ID: mdl-35331394
ABSTRACT
Allogeneic stem cell transplantation is a potentially curative therapy for some malignant and non-malignant disease. There have been substantial advances since the approaches first introduced in the 1970s, and the development of approaches to transplant with HLA incompatible or alternative donors has improved access to transplant for those without a fully matched donor. However, success is still limited by morbidity and mortality from toxicity and imperfect disease control. Here we review our emerging understanding of how reconstitution of effective immunity after allogeneic transplant can protect from these events and improve outcomes. We provide perspective on milestones of immune reconstitution that are easily measured and modifiable.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Immune Reconstitution / Graft vs Host Disease Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cytotherapy Journal subject: TERAPEUTICA Year: 2022 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Immune Reconstitution / Graft vs Host Disease Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cytotherapy Journal subject: TERAPEUTICA Year: 2022 Type: Article Affiliation country: United States